View Post

AACR 2019: Maintenance Rucaparib Treatment in BRCA- or PALB2-Mutated Pancreatic Cancer

In Clinical Trials by Barbara Jacoby

By: The ASCO Post From: ascopost.com Maintenance treatment with the PARP inhibitor rucaparib was well tolerated and showed activity among patients with advanced BRCA– or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical trial presented by Reiss Binder et al at the American Association for Cancer Research (AACR) Annual Meeting …

View Post

Roche’s ipatasertib combo shows early promise in triple-negative breast cancer

In Clinical Trials by Barbara Jacoby

By: Anna Smith From: pharmatimes.com Roche has announced results from a Phase Ib trial assessing its AKT-inhibitor ipatasertib, Tecentriq (atezolizumab) and chemotherapy in triple-negative breast cancer (TNBC), showing a 73% overall response rate irrespective of PD-L1 status. Out of the first 26 subjects in the study, 19 had confirmed responses.The trial consisted of two arms; ipatasertib in combination with Tecentriq and …

View Post

Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Studies support synergistic role of p53 stabilization by APR-246 in combination with immuno-oncology agents Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the …

View Post

Cyclacel Pharma (CYCC) Presents Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

In Clinical Trials by Barbara Jacoby

From: streetinsider.com Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced Phase 1 clinical data from the company’s DNA damage response program with an oral, sequential regimen of sapacitabine and seliciclib as a treatment in patients with BRCA mutant metastatic breast cancer. Data from the study was presented today at the 2019 American Association for Cancer Research (AACR) Annual Meeting and demonstrated that …

View Post

Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting

In Clinical Trials by Barbara Jacoby

Source: Constellation Pharmaceuticals , Inc. From: globenewswire.com Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patients Recently initiated Phase 2 portion of ProSTAR includes randomized testing of CPI-1205 in combination with enzalutamide versus enzalutamide alone, as well as CPI-1205 in combination with abiraterone Initial update from Phase 2 portion of ProSTAR expected in …

View Post

UC San Diego Health treats 1st cancer patient with stem-cell derived natural killer cells

In Clinical Trials by Barbara Jacoby

Source: University of California-SanDiego From: eurekalert.org After 10 years in remission, Derek Ruff’s cancer returned, this time as stage IV colon cancer. Despite aggressive rounds of chemotherapy, palliative radiotherapy and immunotherapy, his disease progressed. In February 2019, as part of a phase I clinical trial at Moores Cancer Center at UC San Diego Health, Ruff became the first patient in …

View Post

Immunotherapy combination effective for patients with rare neuroendocrine cancer

In Clinical Trials by Barbara Jacoby

Source: SWOG From: eurekalert.org A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. Results from the SWOG Cancer Research Network trial known as DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, show …

View Post

Imvax Announces Positive Results from Clinical Trial of Novel IGV-001 Autologous Cell Vaccine in Treating Patients with Newly Diagnosed Glioblastoma

In Clinical Trials by Barbara Jacoby

Source: Globe Newswire From: apnews.co Median overall survival was 21.9 months for highest vaccine dose vs. 14.6 months in published standard of care studies Median progression-free survival was 10.4 months vs. 6.9 and 5.4 months in published standard of care studies Imvax, Inc., a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies, today announced …

View Post

Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.comrec Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. Tisotumab vedotin is being developed in collaboration …

View Post

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the …